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1682-606X/Copyright ª 2014, TaiwanSummary Background: Malignant fibrous histiocytoma (MFH) is a common soft-tissue
sarcoma in adults, which commonly affects the extremities, trunk, head, and neck. Of these
regions, the extremities are more often affected. However, only a few studies have specifically
investigated the clinical behavior and prognosis of this malignancy, especially in East Asian
populations.
Aims and objectives: We collected data on MFH cases for a period of 10 years and present our
experience here in treating patients with extremity MFH.
Materials and methods: This study was a retrospective analysis of patients with extremity MFH
treated in the Department of Plastic Surgery at National Cheng Kung University Hospital
between January 2004 and December 2013. Data on patient profiles, surgical resection, radio-
therapy, and chemotherapy were all reviewed. The patients were followed up regarding their
local recurrences and survivals.
Results: Thirteen patients (6 men and 7 women) were enrolled in this study. The mean age of
the patients was 57.9 years (range, 33e82 years). The sizes of the clinical tumors ranged from
1.7 to 15 cm in a maximal linear dimension (mean, 7.3 cm), and 76.9% of the tumors developed
in the lower extremities. The average follow-up time was 63.5 months. One patient received
limb amputation, and 12 patients were treated with limb salvage including marginal or wide
excisions. Adjuvant radiotherapy was performed in 10 patients whose tumor sizes exceeded
5 cm or who exhibited inadequate excision or recurrence. Chemotherapy was performed in
six patients who exhibited a distant metastasis or vessel invasion. The local and distantng authors declare no conflicts of interest.
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2 K.-H. Chen et al.recurrence rates were 53.8% and 30.8%, respectively. A total of 42.9% of patients with local
recurrence developed distant metastases. The surgical margin was the only significant factor
of local disease control, and distant metastasis was the only factor relevant to the overall sur-
vival (OS).
Conclusion: An adequate resection margin during treatment for the primary MFH tumor
achieves optimal results for local disease control. It influences the OS rate, because local-
recurrence-related distant metastasis is significantly associated with high mortality.
Copyright ª 2014, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Malignant fibrous histiocytoma (MFH) is a pleomorphic sar-
coma originally described by Ozzello et al1 in 1963 and
O’Brien and Stout2 in 1964. It is one of themost common soft-
tissue sarcomas among adults, with a peak incidence be-
tween 60 and 70 years of age.3 It has been determined to
exhibit large, high-grade, and biological aggressiveness.
Most MFHs occur in the extremities (49% in the lower and 19%
in the upper extremities), followed by the trunk and retro-
peritoneum.3 MFH has been categorized into storiform-
pleomorphic, myxoid, giant-cell, and inflammatory types.4
The tumors involving extremities frequently present as a
painless and enlarging mass over a period of months.5 By
contrast, patients with retroperitoneal tumors can exhibit
constitutional symptoms, including anorexia, weight loss,
fever, and malaise.3 A multidisciplinary team is necessary to
manage malignant soft-tissue tumors, and extremity MFH is
the most common type that plastic surgeons treat.
In this study, we retrospectively analyzed the factors
influencing tumor recurrence and survival rates of patients
treated for extremity MFH.2. Materials and methods
We retrospectively analyzed all patients with MFH who were
treated in the Department of Plastic Surgery at National
Cheng Kung University Hospital between January 2004 and
December 2013. The histological diagnosis was confirmed by
the Department of Pathology at our institution. We excluded
all tumors of the retroperitoneum as well those of the head
and neck because of their distinct behaviors and unfavorable
outcomes. In each case, the extent of the tumor was deter-
mined using computed tomography or magnetic resonance
imaging. All the patients underwent chest radiography or
computed tomography to exclude any pulmonary metasta-
ses. The sizes of the tumors were determined based on the
maximal dimension measured in the pathology specimen.
Local disease-free survival (LDFS) was defined as the time
interval fromthedefinite surgical treatment to thedetection
of a recurrent tumor. Overall survival (OS) was defined as the
length of time, from either the date of diagnosis or the start
of treatment for MFH, that patients remained alive. The end
point of this study was reached when patients died or at the
final follow-up date (including contact by telephone).
All patients underwent surgical ablation of their tumors.
Three types of tumor resection were performed: (1) radicalresection, including amputation or removal up to the
adjacent normal fascia plane or the boundary of the adja-
cent healthy tissue, (2) wide resection, involving complete
removal of the gross tumor with at least a 1e2-cm margin to
the adjacent normal tissue, and (3) marginal resection,
involving the removal of the gross tumor with no attempt to
remove normal tissue. The patients were followed up
regarding their local recurrences and survivals. The patients
without regular treatment in our institution were excluded
from this review. All patients were treated by tumor reex-
cision if local MFHs recurred. The dosage applied by radia-
tion oncologists in the postoperative radiation therapy was
50e70 Gy. Adjuvant chemotherapy was performed by on-
cologists adopting a doxorubicin-based regimen.
Clinical and pathologic factors, including age, sex, tumor
location, tumor size, excisionmethod, and adjuvant therapy
(radiotherapy and chemotherapy), were reviewed and
analyzed regarding their influence on the outcome. For data
analysis, the age was categorized into the <50-year-old and
S50-year-old groups, when the tumor was first diagnosed.
The tumor size was categorized into groups of<5, 5e10, and
>10 cm, according to the largest dimension. All statistical
analyseswereperformedusing a statistical softwarepackage
(PASW forWindows, version 18.0; SPSS Inc, Chicago, IL, USA).
Differences of categorical variables were compared with
those of Cox regression analysis. Levels of significance were
expressed as p values. Actuarial curves for survival and local
control were calculated using the KaplaneMeier method.3. Results
Thirteen patients (7 women and 6men) were included in this
study. The mean age of the patients was 57.9 years (33e82
years). The sizes of the clinical tumors ranged from 1.7 to
15 cm in a maximal linear dimension with a mean of 7.3 cm,
and 76.9% of tumors occurred in the lower extremities.
These lower-extremity tumor sites included the thigh in five
cases (50%), the knee in three cases (30%), and the lower leg
in two cases (20%). One case with femoral condyle andmajor
vessel involvement received above-knee amputation with a
safe margin wider than 5 cm. Two patients with intramus-
cular MFH received compartmentectomy (Table 1). These
three cases (23.1%) were included in the radical excision
group. Three patients (23.1%) received a marginal resection
and seven patients (53.4%) received a wide excision. All
surgical margins were negative for malignant cells. Adjuvant
radiotherapy was arranged in only five cases, and
Table 1 Characteristics of study patients and tumors.
No. Age/sex Tumor site Size (cm) Resection Adjuvant
therapy
LR
(times)
DFS (mo) Mets (mo) a Survival/OS (mo)
1 52/F Femoral
condyle
15 AKA C/T N 107 N Alive/107
2 62/F Thigh 6 ME R/T Y (1) 21 N Alive/97
3 60/M Lower leg 7 WE None Y (5) 6 N Alive/120
4 49/F Thigh 5 WE R/T þ C/T N 83 N Alive/83
5 75/M Forearm 1.7 WE None N 70 N ICH/70
6 58/M Upper arm 5 WE R/T þ C/T Y (1) 24 Chest (24), back (25),
thigh (30)
Multi Mets/75
7 74/F Elbow 6 WE R/T Y (1) 6 N Alive/17
8 33/M Thigh 7 WE R/T þ C/T N 3 Scalp, lung, rib (initial) Lung mets/3
9 46/F Thigh 8 RE R/T N 51 N Alive/51
10 53/F Lower leg 2.5 WE R/T Y (5) 8 N Alive/31
11 82/M Thigh 11 RE R/T N 34 N Alive/34
12 60/F Popliteal
fossa
9 ME R/T þ C/T Y (1) 1 Lung (7) Lung mets/18
13 49/M Popliteal
fossa
12 ME R/T þ C/T Y (2) 2 Lung (8) Lung mets/10
AKA Z above-knee amputation; C/T Z chemotherapy; DFS Z disease-free survival; ICH Z intracranial hemorrhage; LR Z local
recurrence; MEZ marginal excision; MetsZ metastasis; OSZ overall survival; R/TZ radiotherapy; REZ radial excision; WEZ wide
excision.
a Time of distant metastasis [after the diagnosis of malignant fibrous histiocytoma (MFH)].
Extremity malignant fibrous histiocytoma 3chemotherapy was performed in only one case. Concurrent
chemoradiotherapy was performed in five cases.
The follow-up time for all patients ranged from 3 to 120
monthswith ameanof 55.4months. The local recurrence rate
was 53.8% (7/13 cases). The statistic correlation between
the LDFS and independent prognostic factors is presented in
Table 2. There were no significant differences among age,
sex, tumor size, location, and adjuvant therapy. Only a mar-
ginal excision predicted a significantly high recurrence
(Fig. 1). The overall distant-metastasis rate was 30.8% (4/13
cases), and the predominant site formetastasis was the lung.
Three cases died of theMFH disease after lungmetastasis and
one case died of the MFH disease with multiple metastases.
Only one patient died of spontaneous intracerebral hemor-
rhage, whichwas not related to theMFH tumor. The patients
withmetastases in the lunghadamean lifeexpectancyof5.33
months, ranging from 2 to 11months (Table 1). The 5- and 10-
year OS rates were 76.2% and 50.8%, respectively. The sta-
tistic correlationbetween theOS and independent prognostic
factors is presented in Table 3. The significant difference
affecting the OS was determined by the tumor metastasis
(Fig. 2).Therewerenosignificantdifferencesamongage, sex,
tumor size, location, surgery, and adjuvant therapy.
4. Case reports4.1. Case 10: A patientwith an inadequate resection
margin during the first tumor ablation surgery
A 53-year-old woman was referred to National Cheng Kung
University Hospital because of a recurrent MFH. Approxi-
mately 8 months before admission, she underwent a wideexcision for a small mass in the right lower leg in another
hospital. The pathologic finding of the lesion was an MFH
without adequately deep margin (<1 mm). Therefore, she
received adjuvant radiotherapy after the first operation.
She presented to our hospital with a tumor recurrence at
the local site (a 2.5-cm tumor). A wide excision of the
tumor was performed with a split-thickness skin graft
(STSG), following which the patient again received adju-
vant radiotherapy. During the second operation, an
adequate surgical margin was achieved based on the
pathological evidence of an intraoperative frozen section
(Fig. 3). However, the tumor recurred four times in the
following 2 years. A metastatic lesion over the right inguinal
lymph node was also detected. Although the patient was
treated with serial aggressive tumor ablation and various
reconstructive surgeries, including a wide excision of the
tumor with STSG for three consecutive times, groin lymph-
node dissection, and medial hemisoleus muscle rotation
flap (Fig. 4), the disease continued to progress and invaded
the periosteum of the tibia during the final episode (Fig. 5A
and B). A fasciocutaneous rotational flap was applied to
cover the exposed tibial bone (Fig. 5C and D). She was
closely followed up in our outpatient clinic for MFH.
4.2. Case 11: A patient with an adequate resection
margin during the first tumor ablation surgery
An 82-year-old man presented to our outpatient clinic with a
substantial mass in the left posterior medial thigh. He had a
medical history of bradycardia and had undergone a pace-
maker installation. Since then, he had regularly been taking
anticoagulants. The lesion only induced mild tenderness and
erythema. Because of fluctuation over the lesion, a
Figure 1 Local disease-free survival curve of different exc
Table 2 Factors that influenced local disease-free
survival of MFH.
Group Recurrence
(N Z 7)
No recurrence
(N Z 6)
p
Age 0.441
<50 y 1 3
50 y 6 3
Sex 0.933
Male 3 3
Female 4 3
Tumor size (cm) 0.822
<5 1 1
5e10 5 4
>10 cm 1 1
Extremity 0.912
Upper 2 1
Lower 5 5
Limb a 0.138
Proximal 2 4
Distal 5 2
Excision method 0.013 *
Radical 0 3
Wide 4 3
Marginal 3 0
Radiotherapy 0.422
Yes 6 4
No 1 2
Chemotherapy 0.886
Yes 3 3
No 4 3
*p < 0.05.
MFH Z malignant fibrous histiocytoma.
a Distal limb means the lesion below the elbow or knee;
proximal limb means the lesion over the upper arm or thigh.
4 K.-H. Chen et al.hematoma or abscess was suspected. Aspiration was
executed two times in a local clinic. According to his medical
records, some crimson, sticky fluid had been drained. Thus,
the lesion was initially treated as a hematoma. However, the
lesion did not resolve after these treatments but progressed
instead. In our clinic, computed tomographywas performed,
which revealed an oval lesion with an uneven ring enhance-
ment and heterogeneous component within the enhanced
cuff. A necrotic tumor, particularly sarcoma, was therefore
suspected. A tumor biopsy revealed that the specimen
exhibited atypical microscopical sarcomatoid cells. An
enlarged lymph node was palpated in an area of the left
groin. After we ruled out a distant metastasis with a positron
emission tomography scan, the patient underwent com-
partmentectomy and groin lymph-nodes dissection (Fig. 6).
The excised specimen included a residual tumor cuff and a
substantial amount of hematoma-like content (Fig. 7A). The
final pathology report was MFH (Fig. 7BeD). The patient
received radiotherapy after the surgical wound healed
completely. No signs of local recurrence were observed
within a 34-month follow-up period.
5. Discussion
MFH is a pleomorphic sarcoma common among adults be-
tween 60 and 70 years of age.3 It has been determined to
exhibit high-grade and biological aggressiveness. MFH
typically occurs in the extremities and the retro-
peritoneum, predominantly in men. In our study, the ratio
of male to female patients was 6:7. The age of patients
ranged from 33 to 82 years with an average age of 57.9
years. The sex and age distribution slightly differed from
previous studies, because our study used a considerably
smaller sample size.4 In addition, the site of involvement
was mostly located in the lower extremities. Most MFHs
(76.9%) in this study were located in the lower extremities,ision methods for malignant fibrous histiocytoma (MFH).
Table 3 Factors that influenced overall survival of MFH.
Group Mortality
(N Z 5)
Survival
(N Z 8)
p
Age 0.359
<50 y 2 2
50 y 3 6
Sex 0.140
Male 4 2
Female 1 6
Tumor size (cm) 0.933
<5 1 1
5e10 3 6
>10 1 1
Extremity 0.420
Upper 2 1
Lower 3 7
Limb a 0.668
Proximal 2 4
Distal 3 4
Excision 0.168
Radical 0 3
Wide 3 4
Marginal 2 1
Radiotherapy 0.518
Yes 4 6
No 1 2
Chemotherapy 0.180
Yes 4 2
No 1 6
Metastasis 0.018 *
Yes 4 0
No 1 8
Recurrence 0.802
Yes 3 4
No 2 4
*p < 0.05.
MFH Z malignant fibrous histiocytoma.
a Distal limb means the lesion below the elbow or knee;
proximal limb means the lesion over the upper arm or thigh.
Extremity malignant fibrous histiocytoma 5especially in the thigh, with the tumors located mostly in
the subcutaneous layer. The incidence of regional lymph-
node involvement varied between 0% and 15%.3,6 None of
the patients had regional lymph-node involvement at the
time of presentation, and only one patient exhibited a
follow-up local tumor recurrence with groin lymph-node
metastasis (Case 10).
Local recurrence has a substantial influence on the
outcome of treatment. Previous studies have shown that
19e64% of patients with MFH developed local
recurrences.6e12 The recurrence rate of MFH in extremities
was lower than that in other areas. Local recurrence rates in
extremities have been reported to be 19e38%.8,11,13 In our
study, 53.8% (7/13) of patients developed local recurrences.
A low amputation rate and no adequate safe margin are
suspected to cause a high local recurrence. Patients hesi-
tated when amputation was suggested, because they wan-
ted to keep their extremities. In our study, all three (100%)
of the patients who underwent amarginal resection and four
of the seven (57.1%) patients who underwent a wideresection developed local recurrence. No recurrence was
observed in patients who received radical resection (0%).
These observations show that marginal resection is associ-
ated with a high rate of recurrence (p Z 0.013). Contro-
versies about the influence of resection remain. If the
lesions occur in the subcutaneous layer, then they are
excised deep in the subfascial layer with a 2- to 4-cm safe
margin.9 Most surgeons perform function-sparing excisions
with negative microscopic margins whenever possible.
Commonly, a function-sparing excision for MFH in extrem-
ities can be accomplished through compartmentectomy.
This was also performed in the thighs of two of our patients.
However, both compartmentectomy and wide excision have
limitations because of their proximity to adjacent neuro-
vascular structures. Limb amputation is considered when
the MFH invades major vessels and bony structures. In our
study, the general principle of excision in MFH patients was
wide excision of the tumor (with a safe margin of at least
2 cm). Amputation and compartment excision were per-
formed in tumors near neurovascular bundles (Case 1) or
muscle invasion (Cases 9 and 11). In Case 2, an excision bi-
opsy was performed in the first operation. However, the
patient refused a second wide excision. In Cases 12 and 13,
the tumor adhered to a popliteal neurovascular bundle and
the patient refused above-knee amputation.
When adequate surgical margins cannot be accom-
plished, adjuvant radiotherapy should be considered. For
tumors measuring < 5 cm, no further adjuvant radiotherapy
may be necessary if a wide negative margin can be ach-
ieved.14 All but three of our patients received adjuvant
radiotherapy. The reason in Case 1 was a large safe margin
(>5 cm) and adjuvant chemotherapy (major vessel inva-
sion). In Case 3, the patient refused adjuvant radiotherapy;
in Case 5, the patient was an old man with a small-sized
tumor.
In our study, the lower-leg MFH exhibited a higher rate
of recurrence (100%) than that of the thigh and upper ex-
tremities; however, there was no significant difference
because of the small sample size. The reason for the high
recurrence may be due to the thinner subcutaneous tissue
and the fact that the tumors were located closer to the
neurovascular vital structures, thereby resulting in an
inadequate surgical margin.
Previous studies have shown that 20e46% of MFH pa-
tients developed distant metastases.7e11,13,15 The inci-
dence of distant metastases in MFHs did not differ between
extremities and other regions.11e13 The most common site
for metastases was the lung, followed by bone and liver.7,10
According to our research, the incidence of distant me-
tastases was 30.8%. Only one case exhibited distal metas-
tasis at the time of presentation (Case 8). The other three
cases exhibited distant metastasis after local tumor
recurrence (Table 1). Three of seven (42.9%) patients with
local recurrence developed distant metastases, implying
that the distant-metastasis rate would decrease if the local
recurrence could be reduced.
Chemotherapy is generally applied for metastatic dis-
eases and unresectable tumors. However, the role of
chemotherapy in the treatment of MFH is not entirely clear.
Several clinical trials incorporating the chemotherapy drug
doxorubicin have demonstrated trends toward improved
event-free survival without a major impact on the OS. The
Figure 2 Overall survival curve of the metastatic and nonmetastatic groups. MFH Z malignant fibrous histiocytoma.
6 K.-H. Chen et al.results of a large meta-analysis, which included almost
1600 soft-tissue sarcoma patients, concluded that the
addition of chemotherapy improved the OS by <10%.13
Results were more favorable in patients with extremity
tumors than in patients with axial or retroperitoneal tu-
mors. More recently, clinical trials incorporating ifosfamideFigure 3 A 53-year-old female patient with malignant fibrous hist
occurred in the central area of the previous tumor excision site. (B
muscle fascia). (C) The area that was operated on 6 months afterand doxorubicin have demonstrated an improvement in
disease-free survival.16,17 One of the major limitations of
chemotherapy is the toxicity associated with the doses
necessary to have a significant impact on disease-specific
survival. In our study, six patients received chemotherapy
after resection. The major reason for performingiocytoma of the right lower leg. (A) The recurrent tumor lesion
) The defect after wide excision (2-cm safe margin and deep to
the surgery and radiotherapy.
Figure 4 (A) After three wide excisions of the tumor and skin graft, the tumor still recurred. (B, C) After further wide excisions of the
recurrent tumor, thebarefibularbonewasexposedand thehemisoleusmuscleflapwaselevated tocover theexposedfibular bone. (D)The
area that was operated on at the 1-month follow-up after reconstructive surgery with a muscle flap and split-thickness skin graft.
Extremity malignant fibrous histiocytoma 7chemotherapy in this group was the distant metastases
(Cases 6, 8, 12, and 13). The other reasons for chemo-
therapy are the tumor being near a neurovascular bundle
(Case 1) and the patient’s preference (Case 4). However,
four of the six patients died.Figure 5 (A) The tumor recurred 4 months after muscle flap reco
bare tibia bone was exposed. (C) Medial fasciocutaneous flap wa
operated on at the 6.5-month follow-up after fasciocutaneous flapPrevious studies have shown that the 5-year OS rate in
all MFH ranged from 36% to 70%.7,10e13,15,18,19 The general
outcomes of extremity MFHs are superior to those of head-
and-neck and retroperitoneal MFHs.8,11e13 According to our
research, the 5-year survival rate is 76.2%. Clinicalnstruction. (B) After wide excision of the recurrent tumor, the
s rotated to cover the exposed tibia. (D) The area that was
reconstruction.
Figure 6 An82-year-oldmalepatientwithmalignant fibrous histiocytoma of the left thigh. (A) The tumor lesion and operative surface
landmark. (B) The tumor originated from the gracilis (G) and invaded the fascia of the adductor longus and magnus (Add. L&M). (C) The
specimen with groin lymph node (LN) after radical tumor excision included the following: gracilis (G), partial sartorius (S), partial
adductor longus and magnus (Add. L&M). (D) The area that was operated on at the 34-month follow-up after surgery and radiotherapy.
8 K.-H. Chen et al.outcomes of extremity MFHs are associated with multiple
factors. A French multicenter study of 195 MFH patients
showed that tumor staging, resection margin, tumor loca-
tion, histology type, and age of the patients areFigure 7 (A) Gross picture of a specimen showing the main tumo
magnification [hematoxylin and eosin (H&E) stain, 100]. (C) Hy
magnification (H&E stain, 400). (D) KP-1 (CD68, histiocyte antigeindependent predictors of 5-year survival.18 However, in-
dependent prognostic factors have varied among studies.
Sabesan et al. in 2006 stated that, although their results
were not consistent with those of previous studies, ther and the central necrotic area. (B) Histological picture at low
perchromatic spindle cells and delicate blood vessels at high
n) was detected, indicating malignant fibrous histiocytoma.
Extremity malignant fibrous histiocytoma 9primary tumor site may influence the OS.12 In our study, all
patients with distant metastases died, and there was a
significantly higher mortality rate than that in the group
without metastasis (p Z 0.022).6. Conclusion
An adequate resection margin during treatment for the
primary MFH tumor achieves optimal results for LDFS. It
influences the OS rate, because local-recurrence-related
distant metastasis is significantly associated with high
mortality.Acknowledgments
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